Click for full image >>

TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

For Investors

NASDAQ: TGTX

Stock Quote at: Sep 28, 4:00PM EDT

Last: $7.90

Change: ($0.08) (1.00%)

Quotes provided by Google - Min 15 minute delay

News & Events

9.16.16

TG Therapeutics, Inc. Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

8.26.16

TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder

Quick Links